Milestone Pharmaceuticals Inc — Quarterly Financial Statistics (NASDAQ:MIST) | MetaTrader

Open full chart

Financials

Overview Estratto Conto Statistics Dividends

Quarterly Annual

Cash from operating activities 7.02 M6.84 M13.95 M12.57 M9.75 M 43.11 M Cash from investing activities -6.48 M-2.77 M33.58 M9.94 M-34.98 M 5.78 M Cash from financing activities 74 K24 K140 K36 K48.92 M 49.12 M Free cash flow 7.02 M6.84 M13.95 M12.55 M9.75 M 43.09 M

Notizie

Milestone Pharmaceuticals appoints David Sandoval as general counsel

All You Need to Know About Milestone Pharmaceuticals (MIST) Rating Upgrade to Strong Buy

Il trattamento CARDAMYST di Milestone per la TPSV ora disponibile nelle farmacie USA

Milestone’s PSVT treatment CARDAMYST now available in US pharmacies

Milestone Pharmaceuticals: Selling The News On Cardamyst Approval Makes No Sense (MIST)

I regolatori europei accettano la domanda per lo spray nasale etripamil per PSVT

Il sistema spray nasale di Aptar per somministrare il trattamento PSVT appena approvato

Milestone Pharmaceuticals: Cardamyst Beat Placebo, But The Commercial Bar Is Higher (MIST)

TD Cowen alza il rating delle azioni Milestone Pharmaceuticals a Buy dopo l’approvazione FDA

Milestone Pharmaceuticals stock rating upgraded by TD Cowen to Buy on FDA approval

Milestone Pharmaceuticals Inc. (MIST) Discusses FDA Approval and Clinical Insights for CARDAMYST Nasal Spray in PSVT Treatment - Slideshow (NASDAQ:MIST) 2025-12-15

Il titolo Milestone vola dopo l’approvazione FDA del primo spray autogestito per PSVT